Avalo Therapeutics, Inc. (AVTX) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-23

Business type: Asset play

How it makes money

AVTX currently earns no revenue from its lead drug candidate while it undergoes clinical trials.

The company is focused on testing abdakibart for hidradenitis suppurativa, a chronic inflammatory skin disease. It cannot sell the drug until it completes its Phase 2 trial and receives regulatory approval.

What protects it: the moat

Management claims its pipeline of biologics provides a competitive advantage.

The company aims to develop best-in-class treatments for inflammatory diseases. It also intends to acquire or in-license new compounds to grow its portfolio.

What growth costs

AVTX must spend heavily on clinical trials to advance its drug candidates.

Research and development expenses are the main driver of cash consumption. These costs rise as the company moves into later-stage development and manufacturing scale-up.

What could damage it

An inability to secure more funding could force the company to stop developing its drug candidates.

AVTX requires significant capital to fund clinical trials. If it cannot raise more money, it may have to halt its research and development efforts.

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Other companies in Biotechnology